Agronomics Limited Portfolio Company Solar Foods Update

TIDMANIC

Agronomics Limited

26 October 2022

26th October 2022

Agronomics Limited

("Agronomics" or the "Company")

Portfolio Company Solar Foods Receives Novel Food Regulatory Approval for its Solein protein grown with CO2 and Electricity

Agronomics, the leading listing company in cellular agriculture, is delighted to share that its Finnish foodtech portfolio company Solar Foods Oy, "Solar Foods", has received its first regulatory approval in Singapore for its novel protein by the Singapore Food Agency. Agronomics has invested a total of EUR 6 million to date and owns approximately 5.80% of Solar Foods, subject to conversion of the outstanding CLN.

The full announcement is set out below without any material changes.

Solar Foods receives novel food regulatory approval for a protein grown with CO2 and electricity

The regulatory approval for the novel food, given by the Singapore Food Agency (SFA), allows for the sale of food products containing Solein(R) in Singapore. The highly sustainable protein is planned to begin commercial production and sales in 2024.

Finnish foodtech company Solar Foods submitted a novel food dossier on Solein for SFA's consideration in September 2021. Solar Foods first commercial-scale production facility, Factory 01, is set to begin operations in Finland in 2024.

The regulatory approval is a major milestone for both Solar Foods and global food supply in general.

A historic moment for food: "Comparable to the discovery of the potato"

Solein is a new crop to harvest for humankind, probably for the first time in centuries. Disconnected from the limitations of traditional agriculture, this type of production method has the potential to transform the sustainability, availability and transparency of what we eat and where food can be produced.

"I'd compare this to the discovery of the potato: we are introducing an entirely new ingredient to the world of food. It's a watershed moment for how we think of what we eat", commented Solar Foods CEO Pasi Vainikka.

"This is also a huge day for us as a company. The food revolution we have been working towards for years has taken a major step forward and we are highly excited about the prospect of bringing Solein to the market in Singapore. We have tested Solein rigorously in a wide variety of foods over recent years. However, the impact of any food product, no matter how innovative, is truly realised only once it can be put on the plates of consumers."

Singapore is first, but other markets are expected to follow

Solar Foods plans to seek GRAS (Generally Recognized As Safe) status assessment for Solein soon in the United States, and applications for novel food authorisation have been filed earlier in other key markets such as the UK and the European Union.

"As urbanisation continues across the globe, megacities and metropolitan areas like Singapore will need more sustainable solutions to feed their citizens. Solein represents an answer to this challenge; a vision where food is grown with minimal resources and without arable land in deserts, Arctic regions, cities, or even outer space. Our pioneering bioprocess is all about making something that was previously impossible now possible", Vainikka describes.

What is Solein?

-- Solein is a microbial protein-rich powder that contains all the essential amino acids. It can be used to replace existing proteins in a variety of foods, for example in alternative dairy and meat, different snacks and beverages, noodles and pasta, or breads and spreads. It is the first ever novel food disconnected from the limits of traditional agriculture. This type of production method has the potential to transform the sustainability, availability and transparency of what we eat and where food can be produced.

-- Solein is produced using a bioprocess where microbes are fed with gases (carbon dioxide, hydrogen, and oxygen) and small amounts of nutrients. The bioprocess resembles winemaking, with carbon dioxide and hydrogen replacing sugar as the source of carbon and energy, respectively.

-- Solein is 65-70% protein, 5-8% fat, 10-15% dietary fibres and 3-5% mineral nutrients. The macronutrient composition of Solein cells is very similar to that of dried soy or algae. Solein provides iron and B vitamins and is exceptionally functional. Solein can be used with a wide variety of other ingredients: it vanishes into foods and doesn't change the taste of familiar, everyday food products.

-- The production of Solein is not reliant on agriculture, weather, or climate: it can be produced in harsh conditions such as deserts, Arctic areas, even space. The process does not require animals or photosynthetic plants, making Solein the world's most sustainable protein.

-- Solein will become available for commercial use for the first time. It is aimed at food brands looking for nutritious, functional, and sustainable protein ingredients of consistent quality that can be reliably delivered for their products. Singapore is the first market to grant Solein a regulatory approval, but Solar Foods is also seeking authorisations in other markets across the world.

-- Factory 01 is Solar Foods' first commercial production facility, which will begin to produce Solein in 2024. Construction of the facility started in Vantaa, Finland during Q4 2021. Factory 01 will scale Solein production to a level where it can be brought to market for the first time. Solar Foods has plans to expand its network of production facilities in the coming years.

   --    Learn more about Solein at www.solein.com 

For more information and requests for interviews:

Solar Foods Ltd.

Pasi Vainikka

DSc (Tech), CEO

[e-mail]

[phone]

About Solar Foods Ltd .

Solar Foods produces protein using carbon dioxide and electricity. Solein production, independent of weather and climate conditions, liberates global protein production from the constraints of traditional agriculture. Solar Foods was founded in Espoo, Finland, in 2017 by Dr Pasi Vainikka, Dr Juha-Pekka Pitkänen, Sami Holmström, Jari Tuovinen, Professor Jero Ahola, and Janne Mäkelä as a spinoff from VTT Technical Research Centre of Finland and LUT University. www.solarfoods.com

About Agronomics

Agronomics is a leading listed alternative proteins company with a focus on cellular agriculture and cultivated meat. The Company has established a portfolio of 24 companies at the Pre-Seed to Series C stage in this rapidly advancing sector. It seeks to secure minority stakes in companies owning technologies with defensible intellectual property that offer new ways of producing food and materials with a focus on products historically derived from animals. These technologies are driving a major disruption in agriculture, offering solutions to improve sustainability, as well as addressing human health, animal welfare and environmental damage. This disruption will decouple supply chains from the environment and animals, as well as being fundamental to feeding the world's expanding population. A full list of Agronomics' portfolio companies is available at https://agronomics.im/ .

About Cellular Agriculture

Cellular Agriculture is the production of agriculture products directly from cells, as opposed to raising an animal for slaughter, or growing crops. This encompasses cell culture to produce cultivated meat and materials, and fermentation processes that harness a combination of molecular biology, synthetic biology, tissue engineering and biotechnology to massively simplify production methods in a sustainable manner.

Over the coming decades, the source of the world's food supply traditionally derived from conventional agriculture is going to change dramatically. We have already witnessed the first wave of this shift with the consumer adoption of plant-based alternative proteins but today, we are on the cusp of an even bigger wave of change. This is being facilitated by advances in cellular agriculture. This change is necessary, given scientists claims that if we maintain existing animal protein consumption patterns, then we will not meet the Paris Agreement's goal of limiting warming to 1.5 '

AT Kearney, a global consultancy firm, projects that cultivated meat's market share will reach 35% by 2040. This combined with the Good Food Institute's estimate that a US $1.8 trillion investment will be required in order to produce just 10% of the world's protein using this technology, means that we are on the cusp of a multi-decade flow of capital to build out manufacturing facilities. Funding in the field of cellular agriculture is accelerating, however still less than US$ 4 billion has been invested worldwide since the industry's inception in 2016.

For further information please contact:

 
       Agronomics         Beaumont      Canaccord         Cenkos        Peterhouse 
         Limited           Cornish       Genuity         Securities       Capital             TB Cardew 
                           Limited       Limited            Plc           Limited 
      The Company          Nomad        Joint Broker       Joint       Joint Broker       Public Relations 
                                                           Broker 
                        ----------  ----------------  -------------  ---------------  ------------------------ 
      Richard Reed         Roland     Andrew Potts         Giles       Lucy Williams 
       Denham Eke          Cornish      Harry Rees        Balleny         Charles             Ed Orlebar 
                            James       Alex Aylen       Max Gould       Goodfellow        Alistair Walker 
                           Biddle        (Head of         Michael 
                                        Equities)         Johnson 
                        ----------  ----------------  -------------  ---------------  ------------------------ 
                                                                                          [phone] 

                                                                                                0777 
      +44 (0) 1624        +44 (0)         +44 (0)         +44 (0)         +44 (0)           +44 (0) 7738 
         639396            207 628        207 523         207 397         207 469              724 630 
   [e-mail]       3396           8000             8900            0936       [e-mail] 
                        ----------  ----------------  -------------  ---------------  ------------------------ 
 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAFIFFTIDLRFIF

(END) Dow Jones Newswires

October 26, 2022 04:30 ET (08:30 GMT)